FOLR1 and ovarian carcinoma: For instance, Knutson et al. [19] demonstrated that immunity to FRα is prevalent in patients with breast and ovarian cancers where FRα-reactive lymphocytes having been identified in patients with these cancers and attempts to bolster this natural immunity are being investigated in preclinical and ongoing clinical trials in ovarian cancer and lung cancer [20, 21].